



# Bal Pharma Limited

02/06/2025

To  
The Manager-Listing  
National Stock Exchange of India Ltd  
Mumbai.

BSE Limited  
Mumbai.

Dear Sir,

Sub : Newspaper Publication.

Ref : Compliance with Regulation 47 of SEBI (LODR) Regulations , 2015.

With reference to the above, we are submitting to the exchange newspaper advertisements of abridged Unaudited Standalone and Consolidated financial results of the Company for the quarter and Financial year ended 31.03.2025 announced by the Company on 29.05.2025 and published in Financial Express (English) and Sanjay vani (Kannada), on 31.05.2025.

Please take the intimation on record.

Thanking You.

For Bal Pharma Ltd

Authorized Signatory.

**SUNIL AGRO FOODS LIMITED**  
CIN: L01110KA1985PLC008851  
Regd. Office: Plot No 33-A2, Industrial Area, Chokkiahalli, Hosur, Karnataka - 562 114  
Phone No: +91-83-2791337/2791463 | Website: <http://www.sunilagro.com>

**Extract of the Audited Financial Results for the Year ended March 31, 2025**

Sl. No.	Particulars	For the Quarter ended Dec 31, 2024		For the Year ended March 31, 2025		For the Year ended March 31, 2024	
		(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)
1	Total Revenue from Operations (including other income)	6816.64	21767.14	5376.77	22364.85	114.97	114.97
2	Net Profit for the period before tax and Exceptional Items	2.83	(144.22)	29.92	114.97	114.97	114.97
3	Net Profit for the period before tax (after Exceptional Items)	2.83	(144.22)	29.92	114.97	114.97	114.97
4	Net Profit for the period after tax (after Exceptional Items)	1.99	(103.43)	10.21	87.58	114.97	114.97
5	Total Comprehensive Income (including PFI) (After tax and after Other Comprehensive Income items)	0.29	(152.65)	23.19	39.85	114.97	114.97
6	Equity Share Capital (Share value of Rs. 10/-)	30029	30029	30029	30029	30029	30029
7	Reserves and Provisions (Reserves as shown in the Balance Sheet of previous year)	1282.84	1282.84	1382.50	1519.35	114.97	114.97
8	Earnings per share of Rs. 10/- each (in Rs.)	0.19	(1.16)	0.54	0.32	0.38	0.38
9	(in Paise)	1.9	(11.6)	5.4	3.2	3.8	3.8

**\* For the period only and not annualized**

- The audited financial results of the Company for the year ended March 31, 2025 have been approved by the Board of Directors of the Company at its meeting held on May 29, 2025.
- The statutory auditors have expressed an unqualified audit opinion.
- The financial results of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act 2013 and the Companies (Indian Accounting Standards) Rules, 2015 as amended.
- The above is an extract of the audited financial results of the Company for the year ended March 31, 2025. The full text of the Quarterly Financial Results for the quarter ended March 31, 2025 and the Board Report can be accessed by scanning the QR Code provided below.

By Order of the Board  
For Sunil Agro Foods Limited  
Rajesh Kumar S  
Director and Chief Executive Officer

Place: Bengaluru  
Date: May 29, 2025

**B&B Realty Limited**  
Regd. Office: No 17, 4th Floor, Shah Sultan, Ali Asker Road, Bangalore-560052

**Extract of Audited Financial Results (Standalone) for the Quarter and year ended March, 2025 (in INR Lakhs)**

Particulars	Quarter ended 31/03/2025	Preceding Quarter ended 31/03/2024	Corresponding Quarter ended 31/03/2024	QoQ % Change	YoY % Change
Total Revenue from Operations	124.76	1.00	-	122.77	122.76
Net Profit for the period before tax (after Exceptional Items)	78.22	(10.47)	(18.63)	81.42	115.55
Net Profit for the period after tax (after Exceptional Items)	78.22	(10.47)	(18.63)	81.42	115.55
Net Profit for the period after tax (after Exceptional Items) (after other Comprehensive Income items)	78.22	(10.47)	(18.63)	81.42	115.55
Equity Share Capital (Share value of Rs. 10/- each)	1485.50	1485.50	1485.50	1485.50	1485.50
Earnings per share of Rs. 10/- each (in Paise)	5.27	(1.05)	(1.86)	5.27	115.55
(in Paise)	52.7	(10.5)	(18.6)	52.7	115.5

Note 1: The above Results have been taken into account by the Board of Directors at their Meeting held on 30th May, 2025.  
2: The Segment Reporting as defined in Accounting Standard 17 is not applicable.  
3: There was no stockholders' meeting at the beginning of the quarter and at the end of the quarter.  
The Company has been audited during the quarter and the results are as shown in the Balance Sheet.

By Order of the Board  
Bhavishya  
Managing Director

**BAJAJ FINANCE LIMITED**

Corporate Office: 3rd Floor, Bajaj Finance, Park Road, Park Road, Pune, Maharashtra, India-411004. Branch Office: 2nd Floor 33, Jayalaxmi, Akashe Nagar, Bangalore, Karnataka-560024.

**General Notice Under Section 13(1) of the Securities and Exchange Board of India (SEBI) Act, 1992, regarding the Audit of the Company's Financial Results for the Quarter ended March 31, 2025.**

The Board of Directors of the Company has approved the financial results for the quarter ended March 31, 2025. The results are as follows:

Particulars	Quarter ended March 31, 2025	Preceding Quarter ended March 31, 2024	Corresponding Quarter ended March 31, 2024
Total Revenue from Operations	124.76	1.00	-
Net Profit for the period before tax	78.22	(10.47)	(18.63)
Net Profit for the period after tax	78.22	(10.47)	(18.63)
Equity Share Capital	1485.50	1485.50	1485.50
Earnings per share	5.27	(1.05)	(1.86)

The above information is in accordance with Regulation 33 read with Regulation 47(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

**BAL PHARMA LIMITED**  
CIN: L05110KA1987PLC008368  
Registered Office: #21&22, Bommasandra Industrial Area, Hosur Road, Bengaluru - 560099.  
Ph: 080-41379500/Fax: 080-22354057  
email: [secretarial@balpharma.com](mailto:secretarial@balpharma.com), [www.balpharma.com](http://www.balpharma.com)

**Statement of audited Standalone & Consolidated Financial Results for the 4th Quarter Ended 31.03.2025 and year ended 31.03.2025.**

The Board of Directors of the Company, at the meeting held on May 29, 2025 approved the audited financials results of the Company for the quarter and year ended March 31, 2025 ("Financial Results").

The Abstract of Financial results can be accessed by scanning the QR Code



For and behalf of the Board of Directors  
Bal Pharma Limited  
Sd/-  
Shallesh Shroya  
Managing Director  
Place : Bengaluru  
Date : 30th May, 2025  
Dir: 00048169

Note: The above information is in accordance with Regulation 33 read with regulation 47(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

**SUPER SALES INDIA LIMITED**  
CIN: L11110KA1981PLC001129  
Regd. Office: 34-A, Kalyani Road, Coimbatore - 640016  
Ph: 0422-2224040/405 Fax: 2422-2221427  
Website: [www.super-sales.in](http://www.super-sales.in) | Email: [info@super-sales.in](mailto:info@super-sales.in)

**NOTICE**

Notice is hereby given to the shareholders of the Company pursuant to Rule 6 of the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2015 as under:

In terms of the said Rules, the Company is required to transfer all shares in respect of which dividends are not claimed for the last 7 consecutive years to the demat account of Investor Education and Protection Fund Authority (IEPF Authority).

Hence, all the underlying shares in respect of which dividends are not claimed for the last 7 years from the year 2017-18 have to be transferred to the demat account of IEPF Authority.

The Company has sent individual notices to the latest available addresses of the shareholders whose dividends are lying unclaimed for the last 7 years, advising them to claim the dividends expeditiously.

The statement containing the details of name, folio number, demat account number, number of shares due for transfer etc. is made available in our website [www.super-sales.in](http://www.super-sales.in) for information and necessary action by the shareholders.

It may be noted that in order to comply with the aforesaid mandatory requirement of transfer of shares, the concerned shareholders may be required to take necessary steps including issue of duplicate share certificates by the Company against such physical shares/carry out corporate action against such demat shares.


The shareholders may further note that the details uploaded by the Company on its website should be regarded and shall be deemed as adequate notice in respect of all actions to be taken by the Company for the purpose of transfer of shares to the demat account of IEPF Authority pursuant to the Rules.

Shareholders who have not claimed their dividends from year 2017-18 can write to the Registrar & Transfer Agents M.F. O. Sharma, India Pvt. Ltd. for further details and for making a valid claim for the unclaimed dividends. In case no valid claim has been made, the shares in respect of which the dividends are lying unclaimed for the last 7 years will be transferred to the demat account of IEPF Authority.

In case the concerned shareholders wish to claim the shares after transfer to IEPF, a separate application has to be made to the IEPF Authority in Form IEPF-5, as prescribed under the Rules and the same is available at IEPF website, [www.iepf.gov.in](http://www.iepf.gov.in).

For SUPER SALES INDIA LIMITED  
S.K. RADHAKRISHNAN  
Company Secretary

Place: Coimbatore  
Date: 31.05.2025



indianexpress.com

**I get the inside information  
and get inside the information.**

**Inform your opinion  
with investigative journalism.**

**The Indian EXPRESS**  
— JOURNALISM OF COURAGE —

The Indian Express.  
For the Indian Intelligent.

epaper.financialexpress.com

BENGALURU

